Oxford Biomedica (LON:OXB) Sets New 52-Week High – Still a Buy?

Oxford Biomedica plc (LON:OXB) hit a new 52-week high on Tuesday . The company traded as high as GBX 671.47 and last traded at GBX 658.20, with a volume of 160733 shares trading hands. The stock had previously closed at GBX 658.37.

Analyst Ratings Changes

A number of brokerages recently weighed in on OXB. JPMorgan Chase & Co. cut their price objective on shares of Oxford Biomedica from GBX 490 to GBX 400 and set a “neutral” rating on the stock in a research note on Tuesday, July 15th. Royal Bank Of Canada lifted their price objective on shares of Oxford Biomedica from GBX 800 to GBX 930 and gave the company an “outperform” rating in a research note on Tuesday, August 26th. Canaccord Genuity Group restated a “buy” rating and set a GBX 451 price objective on shares of Oxford Biomedica in a research note on Tuesday, October 7th. Finally, Peel Hunt reaffirmed a “buy” rating and set a GBX 451 target price on shares of Oxford Biomedica in a report on Friday, August 1st. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, Oxford Biomedica currently has an average rating of “Moderate Buy” and a consensus target price of GBX 558.

Oxford Biomedica Trading Down 0.1%

The business has a fifty day moving average of GBX 602.65 and a 200-day moving average of GBX 445.58. The stock has a market capitalization of £792.52 million, a price-to-earnings ratio of -18.20 and a beta of 1.09. The company has a debt-to-equity ratio of 166.48, a current ratio of 2.35 and a quick ratio of 1.67.

Insider Buying and Selling

In related news, insider Dame Kay Davies sold 4,563 shares of Oxford Biomedica stock in a transaction dated Monday, August 18th. The stock was sold at an average price of GBX 500, for a total value of £22,815. Also, insider Roch Doliveux purchased 67,000 shares of the company’s stock in a transaction that occurred on Friday, August 15th. The stock was bought at an average cost of GBX 450 per share, for a total transaction of £301,500. 34.93% of the stock is currently owned by company insiders.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.